The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
Open Access
- 13 May 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 109 (1), 140-149
- https://doi.org/10.1002/cpt.1890
Abstract
Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to children, yet knowledge is lacking on the oral bioavailability in term neonates up until 1 year of age. Furthermore, the dispositions of the major metabolites 1‐OH‐midazolam (OHM) and 1‐OH‐midazolam‐glucuronide (OHMG) after oral administration are largely unknown for the entire pediatric age span. We aimed to fill these knowledge gaps with a pediatric [14C]midazolam microtracer population pharmacokinetic study. Forty‐six stable, critically ill children (median age 9.8 (range 0.3–276.4) weeks) received a single oral [14C]midazolam microtracer (58 (40–67) Bq/kg) when they received a therapeutic continuous intravenous midazolam infusion and had an arterial line in place enabling blood sampling. For midazolam, in a one‐compartment model, bodyweight was a significant predictor for clearance (0.98 L/hour) and volume of distribution (8.7 L) (values for a typical individual of 5 kg). The typical oral bioavailability in the population was 66% (range 25–85%). The exposures of OHM and OHMG were highest for the youngest age groups and significantly decreased with postnatal age. The oral bioavailability of midazolam, largely reflective of intestinal and hepatic CYP3A activity, was on average lower than the reported 49–92% for preterm neonates, and higher than the reported 21% for children> 1 year of age and 30% for adults. As midazolam oral bioavailability varied widely, systemic exposure of other CYP3A–substrate drugs after oral dosing in this population may also be unpredictable, with risk of therapy failure or toxicity.Keywords
This publication has 50 references indexed in Scilit:
- Metabolism of 1′- and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7Drug Metabolism and Disposition, 2010
- Ontogeny of midazolam glucuronidation in preterm infantsEuropean Journal of Clinical Pharmacology, 2009
- In vitro and in vivo glucuronidation of midazolam in humansBritish Journal of Clinical Pharmacology, 2009
- Human renal function maturation: a quantitative description using weight and postmenstrual agePediatric Nephrology, 2009
- EditorialAnnals of the ICRP, 2007
- Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugsClinical Pharmacology & Therapeutics, 2006
- Pharmacokinetics and metabolism of oral midazolam in preterm infantsBritish Journal of Clinical Pharmacology, 2002
- The Single‐Dose Pharmacokinetics of Midazolam and Its Primary Metabolite in Pediatric Patients after Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 2001
- Cytochrome P450 3AClinical Pharmacokinetics, 1999
- Sedation wlth Intravenous Midazolam in the Pediatric Intensive Care UnitClinical Pediatrics, 1997